Literature DB >> 21452309

Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?

Klaus Bendtzen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21452309     DOI： 10.1002/art.30207

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  13 in total

Review 1.  Immunogenicity of biologic agents in rheumatology.

Authors:  Vibeke Strand; Joao Goncalves; John D Isaacs
Journal:  Nat Rev Rheumatol       Date:  2020-12-14       Impact factor: 20.543

2.  IL-1β, IL-17A, CRP and biologics history might serve as potential markers for clinical response to etanercept in rheumatoid arthritis patients.

Authors:  Bo Zhang; Wei Jiang
Journal:  Inflammopharmacology       Date:  2019-08-28       Impact factor: 4.473

3.  Protection from articular damage by passive or active anti-tumour necrosis factor (TNF)-α immunotherapy in human TNF-α transgenic mice depends on anti-TNF-α antibody levels.

Authors:  L Semerano; J Biton; L Delavallée; E Duvallet; E Assier; N Bessis; E Bernier; O Dhellin; G Grouard-Vogel; M-C Boissier
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

Review 4.  Novel mechanisms of action of the biologicals in rheumatic diseases.

Authors:  Cecilia Beatrice Chighizola; Ennio Giulio Favalli; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

5.  Predicting Hemagglutinin MHC-II Ligand Analogues in Anti-TNFα Biologics: Implications for Immunogenicity of Pharmaceutical Proteins.

Authors:  Benjamin J Andrick; Alexandra I Schwab; Brianna Cauley; Lauren A O'Donnell; Wilson S Meng
Journal:  PLoS One       Date:  2015-08-13       Impact factor: 3.240

6.  Antibodies to infliximab and adalimumab in patients with rheumatoid arthritis in clinical remission: a cross-sectional study.

Authors:  Grith P Eng; Klaus Bendtzen; Henning Bliddal; Michael Stoltenberg; Marcin Szkudlarek; Viktoria Fana; Hanne M Lindegaard; Emina Omerovic; Pil Højgaard; Elmo K Jensen; Pierre N Bouchelouche
Journal:  Arthritis       Date:  2015-02-11

7.  Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.

Authors:  Meghna Jani; Hector Chinoy; Richard B Warren; Christopher E M Griffiths; Darren Plant; Bo Fu; Ann W Morgan; Anthony G Wilson; John D Isaacs; KimmeL Hyrich; Anne Barton
Journal:  Arthritis Rheumatol       Date:  2015-05       Impact factor: 10.995

8.  Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study.

Authors:  Grith Petersen Eng; Pierre Bouchelouche; Else Marie Bartels; Henning Bliddal; Klaus Bendtzen; Michael Stoltenberg
Journal:  PLoS One       Date:  2016-09-08       Impact factor: 3.240

9.  Management of Psoriatic Arthritis: Turkish League Against Rheumatism (TLAR) Expert Opinions.

Authors:  Kemal Nas; Erkan Kiliç; Remzi Çevik; Hatice Bodur; Şebnem Ataman; Figen Ayhan; Özgür Akgül; Ayşen Akinci; Zuhal Altay; Erhan Çapkın; Abdullah Zübeyir Dağli; Tuncay Duruöz; Gülcan Gürer; Feride Göğüş; Yeşim Garip; Cahit Kaçar; Ayhan Kamanli; Ece Kaptanoğlu; Taciser Kaya; Hilal Kocabaş; Erhan Ali Özdemirel; Sumru Özel; İlhan Sezer; İsmihan Sunar; Gürkan Yilmaz
Journal:  Arch Rheumatol       Date:  2018-05-21       Impact factor: 1.472

Review 10.  The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases.

Authors:  Meghna Jani; Anne Barton; Richard B Warren; Christopher E M Griffiths; Hector Chinoy
Journal:  Rheumatology (Oxford)       Date:  2013-08-14       Impact factor: 7.580
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.